Paper · 21119661

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.

Lamont FR and 5 others. Br J Cancer, 2011. Cited by 152 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Papers, record 21119661. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21119661

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.; PubMed
Journal: Br J Cancer; PubMed
Year: 2011; PubMed
Publication types: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/21119661/; PubMed
DOI: https://doi.org/10.1038/sj.bjc.6606016; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC3039817/; PubMed
The journal: https://conductscience.org/library/journal-index/0370635; PubMed
Citations, by iCite: 152; iCite
Relative citation ratio, by iCite: 3.45; iCite
Revised in PubMed: 2023-11-05; PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Lamont FR	F R
2	Tomlinson DC	D C
3	Cooper PA	P A
4	Shnyder SD	S D
5	Chester JD	J D
6	Knowles MA	M A

Source PubMed

Topics25

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Apoptosis	Major topic
Benzimidazoles	Major topic
Carcinoma, Transitional Cell	Major topic
Pyrimidines	Major topic
Pyrroles	Major topic
Quinolones	Major topic
Receptor, Fibroblast Growth Factor, Type 1	Major topic
Receptor, Fibroblast Growth Factor, Type 3	Major topic
Urinary Bladder Neoplasms	Major topic
Animals
Blotting, Western
Cell Cycle
Cell Proliferation
Cells, Cultured
Humans
Immunoenzyme Techniques
In Vitro Techniques
Male
Mice
Mice, Inbred BALB C
Mutation
Phosphorylation
Protein-Tyrosine Kinases
Urothelium
Xenograft Model Antitumor Assays

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by
C6228/A5437	Cancer Research UK	United Kingdom		PubMed
C6228/A5569	Cancer Research UK	United Kingdom		PubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References46

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	11,276,432	Fibroblast growth factors.	Genome Biol	2001	https://conductscience.org/library/papers/11276432	PubMed
2	9,139,660	Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors.	Science	1997	https://conductscience.org/library/papers/9139660	PubMed
3	16,619,045	Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway.	Oncogene	2006	https://conductscience.org/library/papers/16619045	PubMed
4	17,384,684	Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.	Oncogene	2007	https://conductscience.org/library/papers/17384684	PubMed
5	16,352,616	Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?	Carcinogenesis	2006	https://conductscience.org/library/papers/16352616	PubMed
6	9,787,135	The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.	Blood	1998	https://conductscience.org/library/papers/9787135	PubMed
7	10,471,491	Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.	Nat Genet	1999	https://conductscience.org/library/papers/10471491	PubMed
8	12,393,535	In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.	Blood	2003	https://conductscience.org/library/papers/12393535	PubMed
9	19,458,078	Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer.	Cancer Res	2009	https://conductscience.org/library/papers/19458078	PubMed
10	11,157,491	Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.	Blood	2001	https://conductscience.org/library/papers/11157491	PubMed

1 to 10 of 46

See all 46 references

Cited by97

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 152 citations.

PMID	Title	Journal	Year	In Papers	Source
42,177,363	FGFR3 oncogenic activation drives oxidative metabolic reprogramming in bladder cancer: a systems metabolomics approach.	Commun Biol	2026	https://conductscience.org/library/papers/42177363	PubMed
41,315,241	MET signaling drives acquired resistance to erdafitinib in muscle-invasive bladder cancer cells.	Cell Death Dis	2025	https://conductscience.org/library/papers/41315241	PubMed
41,179,739	Dysregulation of mRNA splicing in urothelial carcinoma: Clinical, diagnostic and therapeutic implications.	Bladder Cancer	2025	https://conductscience.org/library/papers/41179739	PubMed
40,603,902	FGFR inhibitors promote the autophagic degradation of IFN-γ-induced PD-L1 and alleviate the PD-L1-mediated transcriptional suppression of FGFR3-TACC3 in non-muscle-invasive bladder cancer.	Cell Death Dis	2025	https://conductscience.org/library/papers/40603902	PubMed
40,515,475	A phase II, multicenter, single-arm study of pemigatinib in patients with metastatic or unresectable colorectal cancer harboring FGFR alterations.	Oncologist	2025	https://conductscience.org/library/papers/40515475	PubMed
40,227,644	From Bench to Bladder: The Rise in Immune Checkpoint Inhibition in the Treatment of Non-Muscle Invasive Bladder Cancer.	Cancers (Basel)	2025	https://conductscience.org/library/papers/40227644	PubMed
40,112,217	Targeting COPA to Enhance Erdafitinib Sensitivity in FGFR-Altered Bladder Cancer.	Adv Sci (Weinh)	2025	https://conductscience.org/library/papers/40112217	PubMed
39,764,422	Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives.	Explor Target Antitumor Ther	2024	https://conductscience.org/library/papers/39764422	PubMed
39,536,791	FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development.	J Korean Med Sci	2024	https://conductscience.org/library/papers/39536791	PubMed
39,031,286	The roles of FGFR3 and c-MYC in urothelial bladder cancer.	Discov Oncol	2024	https://conductscience.org/library/papers/39031286	PubMed

1 to 10 of 97

See all 97 cited by

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
DNTT	1,791	PubTator's text mining	https://conductscience.org/library/genes/1791	NCBI Gene
EGF	1,950	PubTator's text mining	https://conductscience.org/library/genes/1950	NCBI Gene
FGF2	2,247	PubTator's text mining	https://conductscience.org/library/genes/2247	NCBI Gene
FGFR1	2,260	PubTator's text mining	https://conductscience.org/library/genes/2260	NCBI Gene
FGFR3	2,261	PubTator's text mining	https://conductscience.org/library/genes/2261	NCBI Gene
MAPK1	5,594	PubTator's text mining	https://conductscience.org/library/genes/5594	NCBI Gene
TERT	7,015	PubTator's text mining	https://conductscience.org/library/genes/7015	NCBI Gene
TP53	7,157	PubTator's text mining	https://conductscience.org/library/genes/7157	NCBI Gene
TXK	7,294	PubTator's text mining	https://conductscience.org/library/genes/7294	NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/21119661

GET https://conductscience.org/api/papers/v1/21119661/references?page=2

API reference For AI assistants